MediciNova Key Executives
This section highlights MediciNova's key executives, including their titles and compensation details.
Find Contacts at MediciNova
(Showing 0 of )
MediciNova Earnings
This section highlights MediciNova's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for MediciNova, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $1.00M | $- | $4.04M | $- | $- |
| Cost of Revenue | $- | $212.43K | $- | $21.34K | $23.94K |
| Gross Profit | $1.00M | $-212.43K | $4.04M | $-21.34K | $-23.94K |
| Gross Profit Ratio | 100.00% | - | 100.00% | - | - |
| Research and Development Expenses | $5.66M | $9.14M | $8.54M | $7.48M | $6.08M |
| General and Administrative Expenses | $4.98M | $5.48M | $5.72M | $6.69M | $7.95M |
| Selling and Marketing Expenses | $257.93K | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.24M | $5.48M | $5.72M | $6.69M | $7.95M |
| Other Expenses | $- | $-247.28K | $-59.50K | $-38.40K | $-46.16K |
| Operating Expenses | $10.90M | $14.63M | $14.25M | $14.18M | $14.03M |
| Cost and Expenses | $10.90M | $14.63M | $14.25M | $14.18M | $14.03M |
| Interest Income | $1.83M | $809.67K | $143.63K | $361.18K | $1.15M |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $20.30K | $212.43K | $26.15K | $21.34K | $23.94K |
| EBITDA | $-9.88M | $-13.85M | $-10.19M | $-14.16M | $-14.01M |
| EBITDA Ratio | -988.00% | - | -252.38% | - | - |
| Operating Income | $-9.90M | $-14.63M | $-10.22M | $-14.18M | $-14.03M |
| Operating Income Ratio | -990.03% | - | -253.02% | - | - |
| Total Other Income Expenses Net | $1.33M | $562.39K | $84.13K | $322.78K | $1.10M |
| Income Before Tax | $-8.57M | $-14.07M | $-10.13M | $-13.86M | $-12.93M |
| Income Before Tax Ratio | -856.85% | - | -250.94% | - | - |
| Income Tax Expense | $3.05K | $2.82K | $2.57K | $-1.65K | $12.66K |
| Net Income | $-8.57M | $-14.07M | $-10.13M | $-13.85M | $-12.94M |
| Net Income Ratio | -857.15% | - | -251.00% | - | - |
| EPS | $-0.17 | $-0.29 | $-0.21 | $-0.31 | $-0.30 |
| EPS Diluted | $-0.17 | $-0.29 | $-0.21 | $-0.31 | $-0.30 |
| Weighted Average Shares Outstanding | 49.05M | 49.05M | 48.60M | 44.41M | 43.16M |
| Weighted Average Shares Outstanding Diluted | 49.05M | 49.05M | 48.60M | 44.41M | 43.16M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $-999.77M | $1.00B | $- | $- | $- | $- | $- | $- | $4.03B | $37.50K | $- | $4.00M | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $5.37K | $5.35K | $5.49K | $5.70K | $54.12K | $53.62K | $47.93K | $54.19K | $60.70K | $49.61K | $6.37K | $- | $6.15K | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-5.37K | $-5.35K | $-999.78M | $999.99M | $-54.12K | $-53.62K | $-47.93K | $-54.19K | $-60.70K | $-49.61K | $4.03B | $37.50K | $-6.15K | $4.00M | $- | $- | $- | $- |
| Gross Profit Ratio | - | 0.00% | - | - | 100.00% | 100.00% | - | - | - | - | - | - | 100.00% | 100.00% | - | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $1.91M | $1.86M | $1.65M | $1.78M | $1.65M | $794.71M | $1.74M | $1.48M | $2.01M | $2.45M | $2.56M | $2.11M | $1.78M | $2.09M | $2.53M | $2.15M | $1.80M | $2.24M | $2.20M | $1.25M |
| General and Administrative Expenses | $1.28M | $1.45M | $1.40B | $1.35M | $839.33K | $1.35B | $1.56M | $1.49M | $1.22M | $1.44M | $1.52M | $1.30M | $325.82K | $1.55M | $1.78M | $2.06M | $1.22M | $1.49M | $2.31M | $1.67M |
| Selling and Marketing Expenses | $- | $- | $62.12K | $-1.35B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.28M | $1.45M | $1.40M | $1.35M | $839.33K | $1.35B | $1.56M | $1.49M | $1.22M | $1.44M | $1.52M | $1.30M | $325.82K | $1.55M | $1.78M | $2.06M | $1.22M | $1.49M | $2.31M | $1.67M |
| Other Expenses | $- | $- | $- | $-16.04K | $-2.20K | $-14.15K | $-23.21K | $-463.31K | $-194.73K | $-8.47K | $-30.34K | $-13.74K | $-14.21K | $-13.38K | $-8.97K | $-22.94K | $-10.50K | $-11.01K | $-4.55K | $-12.34K |
| Operating Expenses | $3.18M | $3.31M | $3.05M | $3.13M | $2.49M | $2.15B | $3.30M | $2.96M | $3.23M | $3.90M | $4.09M | $3.41M | $2.10M | $3.64M | $4.31M | $4.20M | $3.01M | $3.73M | $4.51M | $2.92M |
| Cost and Expenses | $3.18M | $3.31M | $3.05M | $3.14M | $2.49M | $2.15B | $3.30M | $2.96M | $3.23M | $3.90M | $4.09M | $3.41M | $2.10M | $3.64M | $4.31M | $4.20M | $3.01M | $3.73M | $4.51M | $2.92M |
| Interest Income | $390.10K | $447.85K | $435.35K | $397.51K | $436.26K | $437.93M | $451.42K | $509.05K | $427.30K | $253.75K | $91.28K | $37.34K | $36.47K | $36.15K | $34.34K | $36.67K | $37.01K | $37.20K | $63.69K | $223.28K |
| Interest Expense | $- | $- | $- | $- | $45.74K | $- | $- | $- | $- | $253.75K | $91.28K | $37.34K | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $5.18K | $5.18K | $5.37K | $5.35K | $5.49K | $5.70K | $54.12K | $53.62K | $47.93K | $54.19K | $60.70K | $49.61K | $6.37K | $7.17K | $6.15K | $6.45K | $5.86K | $5.22K | $5.21K | $5.06K |
| EBITDA | $-3.18M | $-3.30M | $-3.04M | $-3.13M | $-2.48M | $-1.14M | $-3.30M | $-2.96M | $-3.23M | $-3.89M | $-4.09M | $-3.41M | $-2.10M | $-3.59M | $-4.30M | $-195.08K | $-3.01M | $-3.72M | $-4.51M | $-2.92M |
| EBITDA Ratio | - | - | - | - | 0.25% | -0.11% | - | - | - | - | - | - | -0.05% | -9586.06% | - | -4.88% | - | - | - | - |
| Operating Income | $-3.18M | $-3.31M | $-3.05M | $-3.14M | $-2.49M | $-1.15B | $-3.30M | $-2.96M | $-3.23M | $-3.90M | $-4.09M | $-3.41M | $-2.10M | $-3.60M | $-4.31M | $-201.53K | $-3.01M | $-3.73M | $-4.51M | $-2.92M |
| Operating Income Ratio | - | - | - | - | 0.25% | -114.69% | - | - | - | - | - | - | -0.05% | -9605.17% | - | -5.04% | - | - | - | - |
| Total Other Income Expenses Net | $374.60K | $456.95K | $418.30K | $381.48K | $434.07K | $423.78K | $428.21K | $45.74K | $232.57K | $245.28K | $60.94K | $23.59K | $22.25K | $22.77K | $25.37K | $13.73K | $26.50K | $26.20K | $59.14K | $210.94K |
| Income Before Tax | $-2.81M | $-2.85M | $-2.63M | $-2.75M | $-2.06M | $-723.11K | $-2.87M | $-2.92M | $-3.00M | $-3.65M | $-4.03M | $-3.39M | $-2.08M | $-3.58M | $-4.28M | $-187.80K | $-2.99M | $-3.70M | $-4.45M | $-2.71M |
| Income Before Tax Ratio | - | - | - | - | 0.21% | -0.07% | - | - | - | - | - | - | -0.05% | -9544.45% | - | -4.69% | - | - | - | - |
| Income Tax Expense | $5.54K | $- | $- | $-38.46K | $-433.22K | $-1.15B | $-451.42K | $-45.74K | $2.82K | $-245.28K | $-60.94K | $-23.59K | $-33.90K | $-36.15K | $-34.34K | $-36.67K | $1.65K | $-37.20K | $-63.69K | $-223.28K |
| Net Income | $-2.81M | $-2.85B | $-2.63M | $-2.75M | $-2.06M | $-723.11K | $-2.87M | $-2.87M | $-3.00M | $-3.41M | $-3.97M | $-3.36M | $-2.08M | $-3.58M | $-4.28M | $-187.80K | $-2.99M | $-3.70M | $-4.45M | $-2.71M |
| Net Income Ratio | - | - | - | - | 0.21% | -0.07% | - | - | - | - | - | - | -0.05% | -9544.45% | - | -4.69% | - | - | - | - |
| EPS | $0.00 | $-0.06 | $-0.05 | $-0.06 | $-0.04 | $-0.01 | $-0.06 | $-0.06 | $-0.06 | $-0.07 | $-0.08 | $-0.07 | $-0.04 | $-0.07 | $-0.09 | $0.00 | $-0.07 | $-0.08 | $-0.10 | $-0.06 |
| EPS Diluted | $0.00 | $-0.06 | $-0.05 | $-0.06 | $-0.04 | $-0.01 | $-0.06 | $-0.06 | $-0.06 | $-0.07 | $-0.08 | $-0.07 | $-0.04 | $-0.07 | $-0.09 | $0.00 | $-0.07 | $-0.08 | $-0.10 | $-0.06 |
| Weighted Average Shares Outstanding | - | 49.05M | 49.05M | 49.05M | 49.05M | 49.05M | 49.05M | 49.05M | 49.05M | 49.05M | 49.05M | 49.04M | 48.99M | 48.99M | 48.80M | 47.54M | 44.64M | 44.64M | 44.09M | 43.95M |
| Weighted Average Shares Outstanding Diluted | - | 49.05M | 49.05M | 49.05M | 49.05M | 49.05M | 49.05M | 49.05M | 49.05M | 49.05M | 49.05M | 49.04M | 48.99M | 48.99M | 48.80M | 47.54M | 44.64M | 44.64M | 44.09M | 43.95M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $40.36M | $51.00M | $18.51M | $71.43M | $60.04M |
| Short Term Investments | $- | $- | $39.98M | $- | $- |
| Cash and Short Term Investments | $40.36M | $51.00M | $58.49M | $71.43M | $60.04M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $714.54K | $174.94K | $499.40K | $577.99K | $680.17K |
| Total Current Assets | $41.07M | $51.17M | $58.99M | $72.01M | $60.72M |
| Property Plant Equipment Net | $382.41K | $621.21K | $674.76K | $881.78K | $55.70K |
| Goodwill | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M |
| Intangible Assets | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M |
| Goodwill and Intangible Assets | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $19.00K | $74.15K | $92.79K | $115.49K | $246.24K |
| Total Non-Current Assets | $14.80M | $15.10M | $15.17M | $15.40M | $14.70M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $55.88M | $66.27M | $74.15M | $87.41M | $75.42M |
| Account Payables | $1.10M | $1.00M | $424.65K | $402.74K | $616.63K |
| Short Term Debt | $193.77K | $215.93K | $157.50K | $131.97K | $186.03K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $1.75M | $1.69B |
| Other Current Liabilities | $1.66M | $2.06M | $2.61M | $2.30M | $1.39M |
| Total Current Liabilities | $2.96M | $3.28M | $3.19M | $2.83M | $2.19M |
| Long Term Debt | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $-523.62K | $-694.67K | $1.69M |
| Deferred Tax Liabilities Non-Current | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K |
| Other Non-Current Liabilities | $211.46K | $410.66K | $523.62K | $694.67K | $2.71K |
| Total Non-Current Liabilities | $413.25K | $612.45K | $725.41K | $896.47K | $1.90M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $3.37M | $3.89M | $3.91M | $3.73M | $4.09M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $49.05K | $49.05K | $49.05K | $49.04K | $45.02K |
| Retained Earnings | $-426.75M | $-415.70M | $-407.13M | $-393.06M | $-382.93M |
| Accumulated Other Comprehensive Income Loss | $-135.15K | $-118.09K | $-115.28K | $-98.88K | $-88.22K |
| Other Total Stockholders Equity | $479.34M | $478.15M | $477.44M | $476.79M | $454.30M |
| Total Stockholders Equity | $52.50M | $62.38M | $70.24M | $83.68M | $71.33M |
| Total Equity | $52.50M | $62.38M | $70.24M | $83.68M | $71.33M |
| Total Liabilities and Stockholders Equity | $55.88M | $66.27M | $74.15M | $87.41M | $75.42M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $55.88M | $66.27M | $74.15M | $87.41M | $75.42M |
| Total Investments | $- | $- | $39.98M | $- | $- |
| Total Debt | $193.77K | $215.93K | $157.50K | $131.97K | $184.75K |
| Net Debt | $-40.17M | $-50.78M | $-18.35M | $-71.30M | $-59.85M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $40.36M | $42.28M | $44.34M | $47.14M | $51.00M | $51.51M | $52.88M | $55.26M | $18.51M | $52.51M | $65.23M | $67.70M | $71.43M | $75.03M | $77.79M | $76.30M | $60.04M | $61.66M | $60.44M | $61.33M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $39.98M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $40.36M | $42.28M | $44.34M | $47.14M | $51.00M | $51.51M | $52.88M | $55.26M | $58.49M | $52.51M | $65.23M | $67.70M | $71.43M | $75.03M | $77.79M | $76.30M | $60.04M | $61.66M | $60.44M | $61.33M |
| Net Receivables | $- | $- | $- | $- | $- | $1.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $4.00M | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- |
| Other Current Assets | $714.54K | $- | $1.17M | $724.80K | $174.94K | $488.79K | $645.46K | $775.03K | $499.40K | $641.73K | $723.74K | $1.14M | $577.99K | $1.13M | $1.12M | $1.17M | $680.17K | $893.84K | $605.68K | $835.54K |
| Total Current Assets | $41.07M | $43.27M | $45.51M | $47.86M | $51.17M | $53.00M | $53.52M | $56.03M | $58.99M | $53.15M | $65.96M | $68.83M | $72.01M | $76.16M | $78.91M | $81.47M | $60.72M | $62.56M | $61.05M | $62.17M |
| Property Plant Equipment Net | $382.41K | $434.71K | $478.99K | $559.69K | $621.21K | $669.11K | $723.88K | $620.74K | $674.76K | $718.99K | $773.29K | $832.04K | $881.78K | $946.07K | $68.57K | $48.93K | $55.70K | $28.86K | $32.93K | $38.12K |
| Goodwill | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M |
| Intangible Assets | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M | $4.80M |
| Goodwill and Intangible Assets | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M | $14.40M |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $10.02M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $19.00K | $19.00K | $19.00K | $70.39K | $74.15K | $71.07K | $72.79K | $77.47K | $92.79K | $101.70K | $105.06K | $111.76K | $115.49K | $117.54K | $305.33K | $183.43K | $246.24K | $309.11K | $359.15K | $410.32K |
| Total Non-Current Assets | $14.80M | $14.85M | $14.90M | $15.03M | $15.10M | $15.14M | $15.20M | $15.10M | $15.17M | $25.24M | $15.28M | $15.34M | $15.40M | $15.46M | $14.77M | $14.63M | $14.70M | $14.74M | $14.79M | $14.85M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $55.88M | $58.12M | $60.40M | $62.89M | $66.27M | $68.14M | $68.72M | $71.13M | $74.15M | $78.39M | $81.24M | $84.18M | $87.41M | $91.62M | $93.68M | $96.10M | $75.42M | $77.29M | $75.84M | $77.01M |
| Account Payables | $1.10M | $708.20K | $667.70K | $804.76K | $1.00M | $736.90K | $548.22K | $585.07K | $424.65K | $552.72K | $642.63K | $665.25K | $402.74K | $642.42K | $607.15K | $428.15K | $616.63K | $376.27K | $576.51K | $377.50K |
| Short Term Debt | $193.77K | $201.98K | $190.05K | $217.89K | $215.93K | $205.39K | $201.28K | $142.20K | $157.50K | $167.07K | $183.62K | $163.94K | $131.97K | $150.68K | $- | $- | $186.03K | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $1.89M | $-1.86B | $-2.07B | $- | $- | $- | $- | $- | $1.75M | $1.69M | $1.69B | $1.69B | $1.69M | $1.69B | $1.69B | $1.69B |
| Other Current Liabilities | $1.66M | $1.69M | $1.64M | $1.49M | $2.06M | $1.86M | $2.07M | $1.99M | $2.61M | $3.81M | $3.01M | $2.15M | $2.30M | $1.71M | $1.86M | $1.40M | $1.39M | $1.43M | $2.20M | $1.42M |
| Total Current Liabilities | $2.96M | $2.60M | $2.49M | $2.51M | $3.28M | $2.80M | $2.82M | $2.72M | $3.19M | $4.53M | $3.84M | $2.98M | $2.83M | $4.20M | $2.47M | $1.83M | $2.19M | $1.80M | $2.77M | $1.79M |
| Long Term Debt | $- | $- | $- | $- | $- | $463.84K | $519.68K | $489.38K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $-351.19K | $-410.66K | $-463.84M | $-519.68K | $-489.38M | $-523.62K | $-555.84K | $-587.40K | $-632.87K | $-694.67K | $-737.72K | $1.69M | $1.69M | $1.69M | $1.69M | $1.69M | $1.69M |
| Deferred Tax Liabilities Non-Current | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K | $201.79K |
| Other Non-Current Liabilities | $211.46K | $456.74M | $302.48K | $351.19K | $410.66K | $- | $- | $- | $523.62K | $555.84K | $587.40K | $632.87K | $694.67K | $737.72K | $87.01K | $2.21K | $2.71K | $- | $- | $- |
| Total Non-Current Liabilities | $413.25K | $456.94M | $504.27K | $552.98K | $612.45K | $665.63K | $721.48K | $691.17K | $725.41K | $757.63K | $789.20K | $834.66K | $896.47K | $939.51K | $1.98M | $1.90M | $1.90M | $1.94M | $1.97M | $2.02M |
| Other Liabilities | $- | $-456.49M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $3.37M | $3.05M | $3.00M | $3.06M | $3.89M | $3.47M | $3.54M | $3.41M | $3.91M | $5.29M | $4.63M | $3.81M | $3.73M | $5.14M | $4.45M | $3.73M | $4.09M | $3.74M | $4.75M | $3.82M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $92.80K | $92.80K |
| Common Stock | $49.05K | $49.05K | $49.05K | $49.05K | $49.05K | $49.05K | $49.05K | $49.05K | $49.05K | $49.05K | $49.05K | $49.04K | $49.04K | $49.03K | $48.92K | $48.77K | $45.02K | $44.93K | $44.26K | $43.98K |
| Retained Earnings | $-426.75M | $-423.94B | $-421.08M | $-418.46M | $-415.70M | $-413.64M | $-412.92M | $-410.05M | $-407.13M | $-404.13M | $-400.48M | $-396.45M | $-393.06M | $-390.98M | $-387.40M | $-383.11M | $-382.93M | $-379.94M | $-376.24M | $-371.79M |
| Accumulated Other Comprehensive Income Loss | $-135.15K | $-123.80M | $-131.53K | $-126.98K | $-118.09K | $-123.75K | $-121.04K | $-116.83K | $-115.28K | $-124.26K | $-118.29K | $-106.31K | $-98.88K | $-95.04K | $-93.68K | $-95.04K | $-88.22K | $-90.03K | $-92.80K | $-92.80K |
| Other Total Stockholders Equity | $479.34M | $479.13B | $478.57M | $478.36M | $478.15M | $478.39M | $478.17M | $477.84M | $477.44M | $477.31M | $477.15M | $476.87M | $476.79M | $477.51M | $476.68M | $475.53M | $454.30M | $453.54M | $447.38M | $445.03M |
| Total Stockholders Equity | $52.50M | $55.07B | $57.41M | $59.83M | $62.38M | $64.67M | $65.18M | $67.73M | $70.24M | $73.11M | $76.61M | $80.36M | $83.68M | $86.48M | $89.23M | $92.37M | $71.33M | $73.55M | $71.09M | $73.20M |
| Total Equity | $52.50M | $55.07B | $57.41M | $59.83M | $62.38M | $64.67M | $65.18M | $67.73M | $70.24M | $73.11M | $76.61M | $80.36M | $83.68M | $86.48M | $89.23M | $92.37M | $71.33M | $73.55M | $71.09M | $73.20M |
| Total Liabilities and Stockholders Equity | $55.88M | $58.12M | $60.40M | $62.89M | $66.27M | $68.14M | $68.72M | $71.13M | $74.15M | $78.39M | $81.24M | $84.18M | $87.41M | $91.62M | $93.68M | $96.10M | $75.42M | $77.29M | $75.84M | $77.01M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $55.88M | $58.12M | $60.40M | $62.89M | $66.27M | $68.14M | $68.72M | $71.13M | $74.15M | $78.39M | $81.24M | $84.18M | $87.41M | $91.62M | $93.68M | $96.10M | $75.42M | $77.29M | $75.84M | $77.01M |
| Total Investments | $- | $42.24B | $- | $- | $- | $- | $- | $- | $39.98M | $10.02M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $193.77K | $201.98K | $492.53K | $569.07K | $215.93K | $669.23K | $201.28K | $631.58K | $157.50K | $167.07K | $183.62K | $163.94K | $131.97K | $150.68K | $- | $- | $186.03K | $39.89K | $75.78K | $127.61K |
| Net Debt | $-40.17M | $-42.08M | $-43.85M | $-46.57M | $-50.78M | $-50.84M | $-52.67M | $-54.63M | $-18.35M | $-52.34M | $-65.05M | $-67.53M | $-71.30M | $-74.87M | $-77.79M | $-76.30M | $-59.85M | $-61.62M | $-60.36M | $-61.20M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-11.05M | $-8.57M | $-14.07M | $-10.13M | $-13.85M |
| Depreciation and Amortization | $21.08K | $20.30K | $17.71K | $26.15K | $21.34K |
| Deferred Income Tax | $- | $- | $- | $286 | $-3.44M |
| Stock Based Compensation | $1.19M | $710.71K | $642.52K | $1.72M | $3.18M |
| Change in Working Capital | $-979.56K | $111.99K | $334.10K | $-1.21M | $-169.36K |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-312.35K | $19.24K | $329.01K | $-1.03M | $-224.31K |
| Other Working Capital | $-667.21K | $92.75K | $5.09K | $-181.42K | $54.95K |
| Other Non Cash Items | $173.32K | $297.49K | $163.19K | $216.64K | $3.44M |
| Net Cash Provided by Operating Activities | $-10.64M | $-7.43M | $-12.91M | $-9.38M | $-10.83M |
| Investments in Property Plant and Equipment | $-895 | $-21.30K | $-5.01K | $-28.73K | $-36.49K |
| Acquisitions Net | $- | $- | $5.01M | $- | $- |
| Purchases of Investments | $- | $- | $-59.88M | $- | $- |
| Sales Maturities of Investments | $- | $39.93M | $19.88M | $- | $- |
| Other Investing Activities | $198 | $- | $-5.01M | $-28.73M | $-36.49M |
| Net Cash Used for Investing Activities | $-697 | $39.91M | $-40.01M | $-28.73K | $-36.49K |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $7.92K | $20.89M | $7.30M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $-112.26K | $-192.13K |
| Net Cash Used Provided by Financing Activities | $- | $- | $7.92K | $20.78M | $7.11M |
| Effect of Forex Changes on Cash | $3.96K | $17.27K | $-16.81K | $26.55K | $1.20K |
| Net Change in Cash | $-10.64M | $32.49M | $-52.93M | $11.39M | $-3.76M |
| Cash at End of Period | $40.36M | $51.00M | $18.51M | $71.43M | $60.04M |
| Cash at Beginning of Period | $51.00M | $18.51M | $71.43M | $60.04M | $63.79M |
| Operating Cash Flow | $-10.64M | $-7.43M | $-12.91M | $-9.38M | $-10.83M |
| Capital Expenditure | $-895 | $-21.30K | $-5.01K | $-28.73K | $-36.49K |
| Free Cash Flow | $-10.64M | $-7.45M | $-12.92M | $-9.41M | $-10.86M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-2.81M | $-2.85M | $-2.63M | $-2.75M | $-2.06M | $-723.11K | $-2.87M | $-2.92M | $-3.00M | $-3.65M | $-4.03M | $-3.39M | $-2.08M | $-3.58M | $-4.28M | $-187.80K | $-2.99M | $-3.70M | $-4.45M | $-2.71M |
| Depreciation and Amortization | $5.18K | $5.18K | $5.37K | $5.35K | $5.49K | $5.70K | $5.00K | $4.11K | $4.33K | $4.46K | $4.49K | $4.43K | $6.37K | $7.17K | $6.15K | $6.45K | $5.86K | $5.22K | $5.21K | $5.06K |
| Deferred Income Tax | $- | $- | $- | $- | $346.49K | $371 | $- | $- | $- | $- | $- | $- | $286 | $- | $- | $- | $169.36M | $- | $- | $- |
| Stock Based Compensation | $263.99K | $504.86K | $207.46K | $215.43K | $-237.41K | $219.14K | $325.71K | $403.26K | $128.67K | $158.30K | $274.50K | $81.05K | $-756.97K | $578.94K | $755.90K | $1.14M | $398.05K | $1.03M | $1.15M | $596.38K |
| Change in Working Capital | $569.41K | $1.82M | $-431.76K | $-1.38M | $1.74M | $-921.22K | $108.97K | $-819.31K | $-1.17M | $741.40K | $1.24M | $-472.64K | $-858.87K | $-185.85K | $4.65M | $-4.81M | $632.30K | $-1.24M | $1.21M | $-766.50K |
| Accounts Receivables | $- | $- | $- | $- | $1.00M | $-1.00M | $- | $- | $- | $- | $- | $- | $4.00M | $- | $4.00M | $-4.00M | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $-1.00M | $1.00M | $- | $- | $- | $- | $- | $- | $-4.00M | $- | $- | $-80.07M | $- | $- | $- | $- |
| Accounts Payables | $353.25K | $115.25K | $507 | $-781.35K | $476.91K | $-28.80K | $30.37K | $-459.25K | $-627.10K | $704.14K | $844.76K | $111.35K | $-1.36M | $-16.74K | $726.10K | $-378.87K | $351.80K | $-1.01M | $926.69K | $-493.46K |
| Other Working Capital | $216.16K | $1.70M | $-432.26K | $-602.56K | $1.27M | $-892.42K | $78.60K | $-360.06K | $-545.38K | $37.26K | $393.07K | $-584.00K | $498.15K | $-169.11K | $3.92M | $79.64M | $280.50K | $-234.13K | $281.62K | $-273.04K |
| Other Non Cash Items | $44.34K | $-1.51M | $36.20K | $1.06M | $-298.09K | $47.56K | $49.12K | $152.03K | $33.92K | $27.88K | $56.22K | $45.18K | $53.36K | $163.28K | $42.11K | $1.14M | $-169.36M | $-694.59K | $926.69K | $-493.46K |
| Net Cash Provided by Operating Activities | $-1.93M | $-2.03M | $-2.81M | $-3.87M | $-499.06K | $-1.37M | $-2.38M | $-3.18M | $-4.01M | $-2.72M | $-2.46M | $-3.73M | $-3.64M | $-3.02M | $1.13M | $-3.85M | $-1.95M | $-3.91M | $-2.09M | $-2.88M |
| Investments in Property Plant and Equipment | $2 | $-6 | $- | $- | $22 | $-2.74K | $-18.58K | $- | $-5.01K | $- | $- | $- | $2.94K | $-2.94K | $-25.79K | $- | $-32.70K | $-1.19K | $-10 | $-2.59K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $-4.99M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $-49.88M | $-10.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $39.89B | $- | $- | $39.93M | $19.88M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-1 | $199 | $-891 | $- | $-21.30M | $- | $- | $39.93M | $4.99M | $-10.00M | $- | $- | $-28.71M | $- | $- | $- | $-36.49M | $- | $- | $- |
| Net Cash Used for Investing Activities | $1 | $193 | $-891 | $- | $22 | $-2.74K | $-18.58K | $39.93M | $-30.01M | $-10.00M | $- | $- | $-28.70M | $-2.94K | $-25.79K | $- | $-32.70K | $-1.19K | $-10 | $-2.59K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $7.91M | $- | $7.92K | $- | $38.70K | $249.61K | $389.75K | $20.21M | $562.49K | $5.28M | $1.23M | $426.93K |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $7.92K | $- | $- | $- | $- | $- | $-16 | $-112.24K | $-203.84K | $-147.74K | $-33.94K | $-7.98K |
| Net Cash Used Provided by Financing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $7.92K | $- | $7.92K | $- | $38.70K | $249.61K | $389.74K | $20.10M | $358.65K | $5.13M | $1.20M | $418.95K |
| Effect of Forex Changes on Cash | $10.85K | $-25.34K | $10.85K | $7.61K | $-8.88K | $5.38K | $18.50K | $2.27K | $10.28K | $-5.85K | $-13.94K | $-7.30K | $5.84K | $2.07K | $-457 | $19.10K | $-1.45K | $2.76K | $5 | $-120 |
| Net Change in Cash | $-1.92M | $-2.06M | $-2.80M | $-3.86M | $-507.92K | $-1.37M | $-2.38M | $36.75M | $-34.00M | $-12.73M | $-2.46M | $-3.74M | $-3.59M | $-2.77M | $1.49M | $16.27M | $-1.62M | $1.22M | $-889.82K | $-2.46M |
| Cash at End of Period | $40.36M | $42.28M | $44.34M | $47.14M | $51.00M | $51.51M | $52.88M | $55.26M | $18.51M | $52.51M | $65.23M | $67.70M | $71.43M | $75.03M | $77.79M | $76.30M | $60.04M | $61.66M | $60.44M | $61.33M |
| Cash at Beginning of Period | $42.28M | $44.34M | $47.14M | $51.00M | $51.51M | $52.88M | $55.26M | $18.51M | $52.51M | $65.23M | $67.70M | $71.43M | $75.03M | $77.79M | $76.30M | $60.04M | $61.66M | $60.44M | $61.33M | $63.79M |
| Operating Cash Flow | $-1.93M | $-2.03M | $-2.81M | $-3.87M | $-499.06K | $-1.37M | $-2.38M | $-3.18M | $-4.01M | $-2.72M | $-2.46M | $-3.73M | $-3.64M | $-3.02M | $1.13M | $-3.85M | $-1.95M | $-3.91M | $-2.09M | $-2.88M |
| Capital Expenditure | $2 | $-6 | $-891 | $- | $22 | $-2.74K | $-18.58K | $- | $-5.01K | $- | $- | $- | $2.94K | $-2.94K | $-25.79K | $- | $-32.70K | $-1.19K | $-10 | $-2.59K |
| Free Cash Flow | $-1.93M | $-2.03M | $-2.81M | $-3.87M | $-499.04K | $-1.37M | $-2.40M | $-3.18M | $-4.01M | $-2.72M | $-2.46M | $-3.73M | $-3.64M | $-3.02M | $1.10M | $-3.85M | $-1.98M | $-3.91M | $-2.09M | $-2.88M |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
$1.59
Stock Price
$77.98M
Market Cap
13
Employees
La Jolla, CA
Location
Revenue (FY 2023)
$1.00M
0.0% YoY
Net Income (FY 2023)
$-8.57M
0.0% YoY
EPS (FY 2023)
$-0.17
0.0% YoY
Free Cash Flow (FY 2023)
$-10.64M
-42.8% YoY
Profitability
Gross Margin
0.0%
Net Margin
0.0%
ROE
%
ROA
%
Valuation
P/E Ratio
0.00
P/S Ratio
0.00
EV/EBITDA
0.00
Market Cap
$77.98M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-10.64M
-43.2% YoY
Free Cash Flow
$-10.64M
-42.8% YoY
Balance Sheet Summary
Total Assets
$55.88M
-15.7% YoY
Total Debt
$193.77K
10.3% YoY
Shareholder Equity
$52.50M
-100.0% YoY
Dividend Overview
No Dividend Data
MediciNova, Inc. doesn't currently pay dividends.
MediciNova Dividends
Explore MediciNova's dividend history, including dividend yield, payout ratio, and historical payments.
MediciNova News
Read the latest news about MediciNova, including recent articles, headlines, and updates.
MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025
LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces that their CEO, Yuichi Iwaki, MD, Ph.D., and CBO, David H. Crean, Ph.D., will be participating in investor meetings at D. Boral Capital's, Inaugural DBC Conference on May 14, 2025 at the Plaza Hotel, New York City. The conference will bring together public and private executives with institutional investors, high-net worth individuals, and corporate clients from various sectors including Healthcare & Life Sciences. Drs. Iwaki and Crean will be discussing MediciNova's leading programs in neurologic and metabologic disorders. For more information about participation in the DBC Conference, visit https://dboralcapital.com/conference .
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
LA JOLLA, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment of the first patient in the NIH-funded Expanded Access Program (EAP) trial to evaluate MN-166 (ibudilast) in patients with Amyotrophic Lateral Sclerosis (ALS).
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study update and interim analysis results from the Company's COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) will be presented at the 35th International Symposium on ALS/MND held December 6-8, 2024 in Montreal, Canada.
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
LA JOLLA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a pending patent application for MN-001 (Tipelukast) to cover "Method to Decrease Triglyceride Synthesis in a Liver of a Subject." The allowed claims cover a groundbreaking method for decreasing triglyceride synthesis in the liver by administering MN-001 (Tipelukast) or its metabolite or pharmaceutically acceptable salt. This method is particularly beneficial for subjects diagnosed with insulin resistance, pre-diabetes, or diabetes. Once issued, this patent is expected to expire no earlier than May 26, 2042.
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled. Accordingly, MediciNova is entitled to receive a certain amount of monetary damages through this settlement. Further details will be provided as they become available.
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the lead Principal Investigator of this clinical trial, Björn Oskarsson, MD, FAAN presented the update of an ongoing Phase 2/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients at the 2024 Annual NEALS Meeting being held virtually on Oct 21-24, 2024.
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
LA JOLLA, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS) has awarded $22 million for an intermediate size Expanded Access Protocol (EAP) to evaluate the efficacy of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)1,2.
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
LA JOLLA, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding a clinical trial of MN-166 (ibudilast) in the treatment of Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS study has been selected for a poster presentation at the 35th International Symposium on ALS / MND to be held December 6-8, 2024 in Montreal, Canada. The poster presentation will be presented by lead Principal Investigator of this clinical trial, Björn Oskarsson, MD, FAAN Associate Professor of Neurology at Jacksonville, FL, Director of ALS, Center of Excellence.
MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
LA JOLLA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract was accepted for presentation regarding a clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS Phase 2b/ 3 study at the 2024 Annual NEALS Meeting to be held October 21-24, 2024 (a hybrid meeting in Clearwater, Florida and Online). The presentation will be in poster format and be presented by lead Principal Investigator of the clinical trial, Björn Oskarsson, MD, FAAN, Associate Professor of Neurology at Jacksonville, FL and Director, ALS Center of Excellence.
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
LA JOLLA, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering a therapeutically effective doses of ibudilast (or a pharmaceutically acceptable salt thereof) to alleviate a range of post-COVID conditions including anxiety, fatigue, depression, shortness of breath, post-traumatic stress disorder, chest tightness, palpitations, smell or taste dysfunction, sleep difficulties, hair loss, and rash.
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
LA JOLLA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the prevention of metastasis in various cancers including pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, and ovarian cancer.
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
LA JOLLA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova's collaborator, Gilbert Youssef, M.D. at Harvard Medical School, Attending Physician, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital, presented new data and results of a Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma (GBM) at the American Society of Clinical Oncology (ASCO) Annual meeting 2024 held May 31- June 4th in Chicago, IL.
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
LA JOLLA, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova conducted two poster presentations at the 92nd European Atherosclerosis Society (EAS) 2024 Congress held online May 26-29, 2024.
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
LA JOLLA, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the prevention of metastasis of eye cancer.
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
LA JOLLA, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of chlorine-induced acute respiratory distress syndrome (ARDS).
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
LA JOLLA, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166 (ibudilast). This new patent is expected to expire no earlier than September 2040. The allowed claims cover a formulation in the form of a tablet or capsule and cover a range of doses of MN-166 (ibudilast).
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago. The oral presentation will be presented by one of the investigators of this clinical trial, Gilbert Youssef, M.D., Attending Physician at Harvard Medical School, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital.
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
LA JOLLA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
LA JOLLA, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that two abstracts entitled “ STUDY PROTOCOL TO EVALUATE MN-001'S (TIPELUKAST) EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), HYPERTRIGLYCERIDEMIA (HTG) AND TYPE-2 DIABETES MELLITUS (T2DM )” and “ MN-002, THE METABOLITE OF MN-001(TIPELUKAST) PROMOTES MACROPHAGE CHOLESTEROL EFFLUX ” have been accepted and selected for poster presentation at the 92nd European Atherosclerosis Society (EAS) 2024 Congress to be held May 26-29, 2024.
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
LA JOLLA, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova's collaborator, Perenlei Enkhbaatar, MD, PhD, FAHA, Professor, Department of Anesthesiology, Director, Translational Intensive Care Unit, Charles Robert Allen Professor in Anesthesiology, University of Texas Medical Branch, presented new data and results of a nonclinical study evaluating MN-166 (ibudilast) in a chlorine gas-induced acute lung injury (CIALI) model at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo in Salt Lake City, Utah.
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
LA JOLLA, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Grant from the Chinese Patent Office for a new patent which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
LA JOLLA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury has been selected for a poster presentation at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo to be held March 10 - 14, 2024 in Salt Lake City, Utah. The poster will be presented by MediciNova's collaborator, Perenlei Enkhbaatar, MD, PhD, FAHA, Professor, Department of Anesthesiology, Director, Translational Intensive Care Unit, Charles Robert Allen Professor in Anesthesiology at The University of Texas Medical Branch.
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
LA JOLLA, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Decision to Grant from the European Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis (progressive MS).
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova's collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Patrick Wen, Director at the Center for Neuro-Oncology at Dana-Farber Cancer Institute, Professor of Neurology, Harvard Medical School, presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) held November 15 - 19, 2023 in Vancouver, Canada. The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.
MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
LA JOLLA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of Sanofi, has treated the first patient in a clinical trial of SAR444836 for the treatment of phenylketonuria (PKU). SAR444836 is a phenylalanine hydroxylase (PAH) replacement gene therapy product based on adeno-associated virus (AAV) vector technology which is covered under MediciNova's assignment agreement with Genzyme Corporation.
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
LA JOLLA, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS).
MediciNova Receives Gene Therapy Milestone Payment
LA JOLLA, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a milestone payment under MediciNova's assignment agreement with Genzyme Corporation, a subsidiary of Sanofi. The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV (adeno-associated virus) vector technology that is covered under the assignment agreement.
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
LA JOLLA, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the results of the nonclinical studies conducted under its contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). Two different nonclinical models were used to investigate the potential clinical utility of MN-166 (ibudilast) for the treatment of chlorine-induced lung damage.
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
LA JOLLA, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada. The poster will be presented by MediciNova's collaborator, Dr. Justin Lathia, Vice Chair in the Department of Cardiovascular and Metabolic Sciences and Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at the Lerner Research Institute at Cleveland Clinic; Professor, Department of Molecular Medicine at Case Western Reserve University School of Medicine; and Co-Leader, Molecular Oncology Program, Case Comprehensive Cancer Center.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for MNOV.